AbbVie Wins Upadacitinib Patent Battle Against Hetero in Delaware: Court Affirms 39 RINVOQ® Patent Infringement
What’s Your Next Step in Pharmaceutical IP?
Navigate complex drug patent landscapes based on your needs:
📋 Case Summary
| Case Name | AbbVie, Inc. v. Hetero USA, Inc. |
| Case Number | 1:24-cv-01254-MN (D. Del.) |
| Court | District of Delaware, Chief Judge Maryellen Noreika |
| Duration | Nov 2024 – Aug 2025 302 days |
| Outcome | Plaintiff Win – Permanent Injunction |
| Plaintiff | AbbVie Inc. |
| Defendant | Hetero USA, Inc. & Affiliates |
| Patents at Issue | (and 33 additional patents from the case record) |
| Accused Products | Hetero’s ANDA No. 218859 (Generic Upadacitinib 15mg, 30mg, 45mg) |
Case Overview
The Parties
⚖️ Plaintiff
Global biopharmaceutical company with RINVOQ® (upadacitinib) as a cornerstone of its immunology franchise, generating multi-billion dollar annual revenues.
🛡️ Defendant
Significant generic pharmaceutical manufacturer, along with affiliates Hetero Labs Limited and Hoster Labs Private Limited, operating globally.
Patents at Issue
This landmark case involved 39 U.S. patents covering upadacitinib’s composition, formulation, synthesis, and methods of use, creating overlapping exclusivity layers characteristic of pharmaceutical lifecycle management strategies.
- • US 9,951,080 — Composition of matter
- • US 10,981,923 — Formulation patent
- • US 11,186,584 — Method of use
- • US 11,661,425 — Synthesis process
- • US 11,680,069 — Dosing regimen
- • US 11,718,627 — Extended release formulation
- • and 33 additional patents covering various aspects of upadacitinib.
Developing a similar drug formulation?
Check if your API or formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The court entered a consent order and permanent injunction on August 4, 2025, upon the joint stipulation of AbbVie and the Hetero Defendants. Hetero Defendants admitted that all 39 Asserted Patents are valid, enforceable, and infringed by their ANDA No. 218859. This permanently bars them from manufacturing, using, offering to sell, selling, or importing generic upadacitinib products for the life of these patents.
Key Legal Issues
The stipulated admission of validity and infringement by Hetero is legally significant, highlighting the strength and breadth of AbbVie’s layered patent portfolio. This outcome reinforces the effectiveness of comprehensive “patent thicket” strategies in pharmaceutical lifecycle management and the power of 35 U.S.C. § 271(e)(2)(A) as an enforcement mechanism, enabling injunctive relief years before market entry.
Filing a new pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation and ANDA challenges.
Power Your Pharma Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Pharmaceutical IP
This case highlights critical IP risks in JAK inhibitor development. Choose your next step:
📋 Understand This Case’s Impact
Learn about specific risks and implications from this litigation regarding JAK inhibitors and comprehensive portfolios.
- View all 39 asserted patents and their claim scope
- See which companies are most active in JAK inhibitor IP
- Understand claim construction patterns for similar compounds
🔍 Check My Drug Product’s Risk
Run a comprehensive FTO analysis for your own API, drug formulation, or method of use.
- Input your drug candidate description or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for market entry
High Risk Area
JAK Inhibitor compounds & formulations
39 Patents Asserted
Covering composition, formulation, use
Layered Protection
Early & late-stage patent families
✅ Key Takeaways
For Patent Attorneys
A 39-patent portfolio assertion resulted in full stipulated admission of validity and infringement, demonstrating the defensive power of comprehensive pharmaceutical patent thickets.
Search related case law →Permanent injunctions in ANDA litigations remain achievable through consent orders without trial, providing efficient enforcement pathways.
Explore precedents →Delaware District Court under Judge Noreika continues to be the preeminent forum for complex Hatch-Waxman pharmaceutical patent litigation.
Explore Delaware case stats →The “without prejudice” dismissal structure preserves future enforcement rights across different product configurations.
Understand dismissal terms →For R&D Teams
Upadacitinib’s patent protection extends through multiple patent families with staggered expirations—comprehensive FTO analysis must account for all layers before generic development investment.
Start FTO analysis for my drug →Lifecycle management through continuation filings, extending to 2024 grants, demonstrates the value of sustained prosecution investment for pharma.
Try AI patent drafting →Ready to Strengthen Your Pharmaceutical IP Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes in the pharma sector.